Cingulate therapeutics ipo
WebAbout Cingulate®. Cingulate® (CTx®)is a Phase 3 clinical stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery … WebMar 10, 2024 · The increase from 2024 to 2024 was related to the recognition of $4.6 million of R&D expense for a one-time, noncash compensation charge in the third quarter of 2024 due to the exchange of Profits Interest Units (PIUs) in Cingulate Therapeutics LLC for common stock of Cingulate Inc. prior to the IPO, which was based on the fair value of …
Cingulate therapeutics ipo
Did you know?
WebCingulate Therapeutics has raised a total of $7.6M in funding over 3 rounds. Their latest funding was raised on Jul 11, 2024 from a Venture - Series Unknown round. Cingulate … WebMar 14, 2024 · With sales of ADHD medication increasing 8 percent each year since 2010, Cingulate could be in a position to capture a significant share of the $18 billion total ADHD prescription drug market.
WebCingulate currently has two (2) product candidates, CTX-1301 and CTX-1302, that are being developed to serve the approximate $18 billion annual U.S. ADHD market. A third product candidate, CTX-2103, is being … WebOct 8, 2024 · Cognition Therapeutics priced its IPO at the mid-point. Cognition Therapeutics raised $45.2 million by offering 3.8 million shares in the IPO at $12 each. Previously, the company planned to offer ...
WebCingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation …
WebSep 10, 2024 · Cingulate Inc filed for an IPO, penciling in a modest $58 million raise, and expects to list on NASDAQ under CING ticker. Cingulate has a Phase 3-ready attention deficit hyperactivity...
WebCingulate Therapeutics, LLC (CTx) is a privately held, clinical-stage biopharmaceutical company focused on the development of innovative new products utilizing the Company’s disruptive, proprietary Precision Timed Release™ (PTR™) drug delivery platfo... irish rail dundalk to dublinWebCINGULATE PHARMA LLC DATED AS OF AUGUST 30, 2024 AGREEMENT AND PLAN OF MERGER(this “Agreement”), dated as of August 30, 2024 by and among Cingulate Therapeutics LLC, a Delaware limited liability company (“CTx”), Cingulate Inc., a Delaware corporation and wholly-owned subsidiary of irish rail explorer ticketWebOct 26, 2024 · KANSAS CITY, Kan., Oct. 26, 2024 /PRNewswire/ -- Cingulate Therapeutics, a privately-held, clinical-stage, biopharmaceutical company focused on the development of innovative new products for... port chester check cashingWebCingulate upsized its IPO at pricing on Dec. 7, 2024, to 4.17 million shares, up from 3.57 ... irish rail folding bikesWebApr 10, 2024 · Analyst Forecast. According to 10 analysts, the average rating for CING stock is "Buy." The 12-month stock price forecast is $5.99, which is an increase of 508.12% … port chester costco hoursWebOct 13, 2024 · Comments by IPO Boutique, including our e-mail alerts and advisories are the observations of the staff of IPO Boutique. They are not intended to be absolute recommendations to buy, hold or sell securities but carefully chosen advisory information, or an endorsement of any specific security or trading strategy. irish rail free travel pass bookingWebItaliano. Français. My Account irish rail free travel booking